Store launching soon — browse the catalog and join the waitlist to be notified at launch.
✦USPS Priority Mail1–3 day delivery across the U.S.Free on orders over $200
Store launching soon — browse the catalog and join the waitlist to be notified at launch.
Your cart is empty
Growth Hormone Secretagogue Blend
Also known as Tesamorelin 6mg + Ipamorelin 3mg + CJC-1295 No DAC 3mg
Triad-GH is a research blend supplying tesamorelin, ipamorelin, and CJC-1295 (No DAC) in a single vial.
🚀 Launching soon — join the waitlist to be notified when this product is available.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Triad-GH is a research blend supplying tesamorelin, ipamorelin, and CJC-1295 (No DAC) in a single vial.
Each component is separately characterized in growth-hormone axis research; the combination itself has no published literature.
Third-party tested for purity, ID, quantity.
Triad-GH combines two GHRH-analogue components with a selective ghrelin-receptor secretagogue. Tesamorelin is a growth-hormone-releasing factor analogue characterized in clinical research. CJC-1295 without the drug affinity complex is a modified GHRH(1-29) analogue. Ipamorelin is described as the first selective growth-hormone secretagogue, acting at GHS-R1a.
Combining GHRH-pathway and ghrelin-pathway agents in one vial is a formulation choice. References below come from the component literature.
The components entered research separately: GHRH analogues through work on growth-hormone-releasing factor from the 1980s, and ipamorelin through selective secretagogue screening in the 1990s.
The blend has no separate development history and is a supplier formulation.
Research relevant to Triad-GH is the sum of its components: GHRH-receptor pharmacology, ghrelin-receptor secretagogue activity, and GH/IGF-1 axis regulation. No study has evaluated this specific three-component combination.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Triad-GH. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
PubMedEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291–4304.
PubMedIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
PubMedProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults.
PubMedRelated
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
From$50.00
$60.00
Small molecule studied for metabolic regulation, NAD pathways, and cellular energy signaling
From$40.00
Dual peptide complex studied for actin signaling, tissue regeneration pathways, and recovery system research
From$0.00
Oral peptide format studied for systemic repair signaling and gastrointestinal pathway research
$140.00
